A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

NCT01404117 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study is being redesigned

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: Laquinimod 0.6
DRUG: Laquinimod 1.2
OTHER: Glatiramer Acetate or interferon-beta+ Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.